CS230288B1 - Method of preparing mono-clonal antibodies - Google Patents
Method of preparing mono-clonal antibodies Download PDFInfo
- Publication number
- CS230288B1 CS230288B1 CS799182A CS799182A CS230288B1 CS 230288 B1 CS230288 B1 CS 230288B1 CS 799182 A CS799182 A CS 799182A CS 799182 A CS799182 A CS 799182A CS 230288 B1 CS230288 B1 CS 230288B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- monoclonal antibodies
- antibodies
- clone
- administered
- inactivated
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 241000699670 Mus sp. Species 0.000 claims description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 238000006386 neutralization reaction Methods 0.000 claims description 5
- 230000035931 haemagglutination Effects 0.000 claims description 4
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 4
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 230000003067 hemagglutinative effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 238000001085 differential centrifugation Methods 0.000 claims description 2
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- 210000004754 hybrid cell Anatomy 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 238000003748 differential diagnosis Methods 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Vynález rieši spósob přípravy monoklonálnych protilátok ku kliešťovej encefalitidě.The invention provides a method for preparing monoclonal antibodies to tick-borne encephalitis.
Prvé monoklonálne protilátky bolí připravené v roku 1975 [O. Kohler, C. Milstein: Nátuře 256, 495, (1975)]. Pri přípravě hydridómov ku kliešťovej encefalitido (fúzia myelomových buniek so slezinovými buňkami imunizovaného zvieraťa pomocou polyetylénglykolu) sa získavajú klony, ktoré produkujú protilátky. Po reklómovaní buniek sa finálna propagácia robí v peritoneálnej dutině histokompatibilných zvierat, ktorým sa aplikuje Freundovo adjuvans, reisp. Přistane (2, 6, 10, 14 — tetramethylpentadecane, Koch Light Lab. Ltd. Anglia) za účelom vytvorenia ascitickej tekutiny [M. Novák, M. Grešíková, M. Sekeyová, G. Russ, J. Zikán, M. Pospíšil, F. Ciampor: Acta virol., (1983)].The first monoclonal antibodies were produced in 1975 [O. Kohler, C. Milstein: Nature 256, 495, (1975)]. In the preparation of hydridomas to tick-borne encephalitido (fusion of myeloma cells with the spleen cells of an immunized animal using polyethylene glycol), antibody-producing clones are obtained. After cell reclamation, final propagation is made in the peritoneal cavity of histocompatible animals to which Freund's adjuvant, reisp. Land (2, 6, 10, 14 - tetramethylpentadecane, Koch Light Lab. Ltd. Anglia) to create ascitic fluid [M. Novak, M. Gresikova, M. Sekey, G. Russ, J. Zikan, M. Pospisil, F. Ciampor: Acta virol., (1983)].
Podstata vynálezu spočívá v spósobe přípravy monoklonálnych protilátok, ktorá sa vyznačuje tým, že do peritoneálnej dutiny imbrednej linii myší sa podá inaktivovaný Staphylococcus aureus, ktorý sa inokuluje do ústojného bujónu, inkubuje sa po dobu 18 hodin pri teplote 37 °C a potom sa inaktivuje pri teplote 60 °C po dobu 30 minút, udržuje sa po dobu 18 hodin pri teplote 4 °C; materiál sa opať teplom inaktivuje, scentri2 fuguje sa a v pokusech sa používá sediment.SUMMARY OF THE INVENTION The present invention relates to a method for the preparation of monoclonal antibodies, characterized in that inactivated Staphylococcus aureus is injected into the peritoneal cavity of an imbred line of mice, inoculated into a buccal broth, incubated for 18 hours at 37 ° C. 60 ° C for 30 minutes, held at 4 ° C for 18 hours; the material is again inactivated by heat, scentri2 is fused and sediment is used in the experiments.
Výhoda navrhovaného spósobu přípravy monoklonálnych protilátok proti kliešťovej encefalitidě je, že protilátky specificky reagujú v hemaglutinačno-inhibičnorn teste. Získané monoklonálne protilátky umožňujú oddiferencovať virus kliešťovej encefalitidy od víruBOv čelade Togaviridae. Vynález umožňuje kultiváclu hybridómových buniek v peritoneálnej dutině histokompatibilných myší. Výhoda tejto metody spočívá aj vo vysokej koncentrácii monoklonálnych protilátok.An advantage of the proposed method of preparing monoclonal antibodies against tick-borne encephalitis is that the antibodies specifically react in a hemagglutination-inhibition assay. The monoclonal antibodies obtained make it possible to differentiate tick-borne encephalitis virus from theBO virus in the family Togaviridae. The invention allows a culture of hybridoma cells in the peritoneal cavity of histocompatible mice. The advantage of this method also lies in the high concentration of monoclonal antibodies.
PříkladExample
Inokuluje sa 1000 ml ústojného bujónu so Staphylococcus aureus; inkubuje sa infikovaný bujón po dobu 18 hodin pri teplote 37 °C. Po ínaktivácií Staphylococcus aureus pri teplote 60 °C po dobu 30 minút se nechá stáť po dobu 18 hodin pri 4 °C. Opátovne sa inaktivuje pri 60 °C po dobu 30 minút. Po centrifugách sa získá 2 g sedimentu. Sediment sa resuspenduje v 30 ml bujónu. 1 milillter preparátu obsahuje 60 000 000 buniek. Imbredná línia myší BALB/C sa používá v pokusoch. Myšiam sa podá 1,5 ml inaktivovaného Staphylococcus aureus 54 dní před imunizáciou. Myši ,sa imunizujú virusem kliešťovej encefalitidy, kmeňom Skalica, ktorý je uložený v Cs. zbierke arbovírusov Virologického ústavu SAV v Bratislavě pod označením Clgl a číslom 53 Skalica, pomnoženom na kuřácích embryonálnych buňkách a purifikovanom diferenciálinou centrifugáciou. Prvá dávka virusu, podaná intraperitoneáline obsahuje 5120 hemaglutlnačných jednotiek; druhá dávka podaná po 35 dňoch obsahuje 320 hemaglutinačných jednotiek. Hybridómové linie (myelómová línia PgNSl/1 Ag 4-1) a slezinové lymfoidné buňky, ktoré produkujú moinoklonálne protilátky in vitro sa zisťujú pomocou hemaglutinačno-inhibičného testu s aintigénom kliešťovej encefalitidy, kmen Skalica. Po klonovaní a reklónovaní sa získajú hybridómové linie s trvalou schopnostou produkovat monoklonálne protilátky. Dalej sa udržujú len tie, ktoré sú schopné produkovat moinoklonálne protilátky. V snahe získat velké kvantum monoklonálnych protilátok, myelómové hybridně buňky sa aplikujú BALB/C mýšiam, ktorým sa 54 dní vopred podá inaktivovaný Staphylococcus pyogenes aureus. AsciKlón čísloInoculate 1000 ml of a buccal broth with Staphylococcus aureus; the infected broth is incubated for 18 hours at 37 ° C. After inactivation of Staphylococcus aureus at 60 ° C for 30 minutes, it is allowed to stand for 18 hours at 4 ° C. It is inactivated again at 60 ° C for 30 minutes. After centrifugation, 2 g of sediment is obtained. The sediment is resuspended in 30 ml of broth. One millillter preparation contains 60,000,000 cells. The BALB / C mouse imbred line is used in experiments. Mice are given 1.5 ml of inactivated Staphylococcus aureus 54 days prior to immunization. Mice are immunized with tick-borne encephalitis virus, a Skalica strain that is stored in Cs. Collection of Arboviruses of the Institute of Virology of the Slovak Academy of Sciences in Bratislava under the designation Clgl and number 53 Skalica, propagated on smokers embryonic cells and purified by differential centrifugation. The first dose of virus administered intraperitoneally contains 5120 hemagglutinating units; the second dose given after 35 days contains 320 haemagglutination units. Hybridoma lines (myeloma line PgNS1 / 1 Ag 4-1) and spleen lymphoid cells that produce Moinoclonal Antibodies in vitro are detected using a tick-borne encephalitis haemagglutination inhibition assay, Skalica strain. After cloning and recloning, hybridoma lines are obtained with a sustained ability to produce monoclonal antibodies. Further, only those capable of producing moinoclonal antibodies are maintained. In order to obtain a large number of monoclonal antibodies, myeloma hybrid cells are administered to BALB / C mice that are inactivated with Staphylococcus pyogenes aureus 54 days prior to treatment. AsciClone number
Skalicavitriol
Protilátky opracované acetónom tická tekutina, obsahujúca monoklonáline protilátky má hemaglutinačno-iinhibičný titer 1: 162.240 u klonu č. 9 a 1 : 80 u klonu č. 16 (Tabulka lj. Připravené monoklonálne protilátky sa vyznačujú tým, že obsahujú identické imunoglobulíny triedy M (včasné protilátky), ktorých izotyp ťažkého retazca je μ a typ 1'ahkého retazca je κ. Neutralizačný index po přidaní anti IgM protilátok bol 2,4 u klonu č. 9 a 2,1 u klonu č. 16.The acetone treated antibody containing the monoclonal antibody has a hemagglutination-inhibition titer of 1: 162.240 for clone # 1. 9 and 1:80 for clone no. 16 (Table 1j. Prepared monoclonal antibodies are characterized in that they contain identical class M immunoglobulins (early antibodies) whose heavy chain isotype is μ and the light chain type 1 is κ. The neutralization index after the addition of anti IgM antibodies was 2.4 µ clone # 9 and 2.1 for clone # 16.
Monoklonálne protilátky majú velký význam v zdravotnické) diagnostike i v základném výskume. Umožňuje sa štandardizácia produktu a diferenciálna diagnostika.Monoclonal antibodies are of great importance in medical diagnostics as well as in basic research. Product standardization and differential diagnostics are possible.
T a b u 1' k a 1T a b u 1 'k a 1
Výsledky hemaglutinačno-inhibičného a neutralízačného testu s monoklonálmymi protilátkami ku kliešťovej encefalitidě, připravenými v ascitickej tekutině BALB/C myší za použitia inaktivovaných Staphylococcus aureusResults of hemagglutination-inhibition and neutralization test with monoclonal antibodies to tick-borne encephalitis prepared in ascitic fluid of BALB / C mice using inactivated Staphylococcus aureus
Titer hemaglutinačno-inhibičných protilátok Neutralizačný index s antigénom monoklonálnych protilátokTiter of haemagglutination-inhibiting antibodies Neutralization index with monoclonal antibody antigen
Protilátky opracované Do neutralízačného telsacetónom . a 2-merkap- tu boli přidané amtitoethanolom -IgM protilátkyAntibodies treated by neutralizing with telsacetone. and 2-mercapto were added with amtitoethanol -IgM antibody
162.240162240
8080
2,42.4
2,12.1
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS799182A CS230288B1 (en) | 1982-11-10 | 1982-11-10 | Method of preparing mono-clonal antibodies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS799182A CS230288B1 (en) | 1982-11-10 | 1982-11-10 | Method of preparing mono-clonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS230288B1 true CS230288B1 (en) | 1984-08-13 |
Family
ID=5429935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS799182A CS230288B1 (en) | 1982-11-10 | 1982-11-10 | Method of preparing mono-clonal antibodies |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS230288B1 (en) |
-
1982
- 1982-11-10 CS CS799182A patent/CS230288B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eshhar et al. | Generation of hybridomas secreting murine reaginic antibodies of anti-DNP specificity. | |
| Walsh et al. | Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein | |
| Lachmann et al. | Three rat monoclonal antibodies to human C3 | |
| Mathews et al. | Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies | |
| AU596070B2 (en) | Anti-idiotype antibodies & their use in inducing immulogical response to viruses & tumours | |
| JPS592276B2 (en) | Method for producing virus antibodies | |
| WO1988003565A1 (en) | Antibodies | |
| MX2014014412A (en) | Compositions and methods related to prevention and treatment of rabies infection. | |
| EP1530579B1 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
| USRE32833E (en) | Screening vaccines and immunization process | |
| US4490358A (en) | Screening vaccines and immunization process | |
| Craig et al. | Murine hybridoma-derived antibodies in the processing of antigens for the immunodiagnosis of hydatid (Echinococcus granulosus) infection in sheep | |
| Doherty et al. | Breakdown of the blood-cerebrospinal fluid barrier to immunoglobulin in mice injected intracerebrally with a neurotropic influenza A virus: post-exposure treatment with monoclonal antibody promotes recovery | |
| WO2010132872A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists | |
| Lange et al. | Production and characterization of monoclonal antibodies to Rickettsia rickettsii | |
| Saravolatz et al. | Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients | |
| Iwai et al. | Immunoglobulin classes of anti‐Sendai virus antibody detected by ELISA in infected nude mouse serum | |
| CS230288B1 (en) | Method of preparing mono-clonal antibodies | |
| US7071319B2 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
| CN114805570B (en) | Anti-human ACE2 monoclonal antibody and application thereof | |
| HUT72546A (en) | Production of human monoclonal antibodies active against hepatitis b surface antigen | |
| Prabhakar et al. | Monoclonal antibody techniques applied to viruses | |
| EP0581108A2 (en) | Bispecific antibody reactive with sialyl-Lea antigen and CD3 | |
| Shibuta et al. | Differences in bovine parainfluenza 3 virus variants studied by monoclonal antibodies against viral glycoproteins | |
| Masuho et al. | Development of a human monoclonal antibody against cytomegalovirus with the aim of a passive immunotherapy |